

Special Issue

United in the Prevention of Bacterial Resistance during the COVID-19 Era

Message from the Guest Editors

The antimicrobial resistance is inducing an increasingly significant burden on public health, this issue becoming even more pronounced in the context of COVID-19 pandemic. The infection with SARS-CoV 2, until recently an absolutely unknown element in the landscape of infectious pathology. And a systematic, early, and often non-judicious administration of antibiotics has been observed, even in the absence of any data attesting to a co-infection. An eventual later development of a true superinfection often necessitated therapy escalation or an extension of the administration period of the initial antibiotic regimen. Last, but not least, it is worrisome that the dramatic increase in misuse or overuse of reserve antibiotics, with difficult to quantify consequences concerning the resistance patterns of certain germs or the mortality rates associated with these infections. The main purpose of this Special Issue is to provide a platform for sharing with us your experience gained during the COVID-19 pandemic period. Therefore, original research and reviews from interdisciplinary areas focusing on antibiotic therapy and antibiotic resistance related to COVID-19 will be of great interest.

Guest Editors

Prof. Dr. Egidia Gabriela Miftode

Prof. Dr. Gabriel Adrian Popescu

Dr. Simin-Aysel Florescu

Deadline for manuscript submissions

closed (30 June 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/123577

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)